Immucor's ABS2000 Cleared by FDA For Use in U.S.
First Fully Automated Blood Bank System Increases Safety and Productivity
NORCROSS, Ga., July 6 /PRNewswire/ -- Immucor, Inc. (Nasdaq: BLUD), maker of blood bank reagents and related products, announced today that the U.S. Food and Drug Administration (FDA) has cleared the ABS2000 for marketing in the United States. The ABS2000 is the first fully automated, walk-away instrument for the hospital blood bank transfusion laboratory.
Commenting on this clearance, Edward L. Gallup, President, stated, "This is a major milestone in the history of Immucor. The ABS2000 offers our customers significant labor reduction while increasing productivity and patient safety. This system completes our instrument family which also includes the DIAS PLUS and the Rosys Plato. We are the only company with automated solutions for the three market segments; hospital blood banks, donor centers and reference laboratories."
Commenting further, Mr. Gallup stated, "The ABS2000 is our flagship product. There are more than 2,500 facilities in the U.S. that can benefit from the quality and productivity improvements provided by the ABS2000. We believe we have a major advantage in the U.S. market as we are not aware of any competitive instrument which will enter the market in the foreseeable future. There are currently over 20,000 patient test results reported monthly on the ABS2000 placements in Europe and Canada."
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.
For more information on Immucor, please visit the Company's website at www.immucor.com.
This press release may contain forward-looking statements as that term is defined in the Private Securities Reform Act of 1995, including, without limitation, statements concerning the Company's expectations, beliefs, intentions or strategies regarding the future. All forward-looking statements included in this document are based on information available to the Company on the date hereof, and the Company assumes no obligation to update any such forward-looking statements. Further risks are detailed in the Company's filings with the Securities and Exchange Commission, including those set forth in the Company's most recent Form 10-K and Quarterly Reports on Form 10-Q.
|
